BIIB - Biogen Inc.
| Previous Close | 227.18 |
| Open | 227.28 |
| Bid | 225.53 x 800 |
| Ask | 226.40 x 800 |
| Day's Range | 221.53 - 227.80 |
| 52 Week Range | 216.12 - 388.67 |
| Volume | 2,760,973 |
| Avg. Volume | 2,259,432 |
| Market Cap | 44.533B |
| Beta (3Y Monthly) | 1.85 |
| PE Ratio (TTM) | 10.49 |
| EPS (TTM) | 21.58 |
| Earnings Date | Apr 24, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 261.19 |
- Zacks•3 days ago
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
- Motley Fool•4 days ago
Here's Why Ionis Pharmaceuticals Slumped Today
Information from competitors and a collaborator sent the high-flying biotech lower.
- Motley Fool•4 days ago
2 Beaten Down Bluechips: Are They Buys?
Sometimes opportunity comes in the shape of trouble.
- Zacks•4 days ago
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•6 days ago
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.
Yahoo Finance•6 days agoGoldman Sachs's 20 best stocks to invest in now
What are the best stocks to buy after a major rally amid heightened macro risks?
- Motley Fool•7 days ago
Better Buy: Gilead Sciences vs. Biogen
Which stock wins in a battle of two big biotechs?
- GlobeNewswire•9 days ago
Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
Adults with later-onset spinal muscular atrophy (SMA) who are not being treated show increased rates of hospital admissions, clinical interventions and mortality, indicating an.
Bloomberg•11 days agoAn AI Firm Wants to Predict Costly Pharma Flops
A German artificial-intelligence firm had come to a different conclusion. Innoplexus AG, a closely held company based in the outskirts of Frankfurt, uses an algorithm to analyze pharma companies’ drug pipelines that it says takes more data and context into account than any other tool. Its assessment of Biogen’s aducanumab gave about a 70 percent to 90 percent chance that the trial would miss its goal.
- Motley Fool•15 days ago
Should Biogen Investors Be Extra Nervous Right Now?
The biotech giant's most important drug is under a microscope and it doesn't look pretty.
- Simply Wall St.•17 days ago
Here's What Biogen Inc.'s (NASDAQ:BIIB) P/E Ratio Is Telling Us
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it prac...
- Motley Fool•17 days ago
1 Biotech That Biogen Should Buy ... but Probably Won't
The drugmaker has $4.9 billion in the bank.
- Motley Fool•17 days ago
Why Biogen Stock Tanked in March
The biotech's misstep in Alzheimer's disease proved costly for shareholders last month.
- Reuters•18 days ago
UPDATE 1-Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group
Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday. Assessments by the nonprofit Institute for Clinical and Economic Review (ICER) have become increasingly influential in U.S. drug pricing and are taken into consideration by health insurers and pharmacy benefit managers making decisions about payments and patient access to treatments. Boston-based ICER has been looking at Biogen's Spinraza and Novartis' Zolgensma since last year.
- Motley Fool•18 days ago
Why Nightstar Therapeutics Stock Skyrocketed 71% in March
The clinical-stage gene therapy company got some love from biotech giant Biogen last month.
- Zacks•19 days ago
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks•20 days ago
Celgene Gets Positive CHMP Nod for Revlimid Label Expansion
Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.
- Zacks•20 days ago
Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval
Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
- Motley Fool•22 days ago
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.
- Zacks•23 days ago
4 Small Biotech Stocks Likely to Witness More Upside in 2019
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
- Motley Fool•24 days ago
Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?
Biogen's pipeline pitfall casts doubt on its strategy. Meanwhile, a shareholder revolt threatens Bristol-Myers' tie-up with Celgene.
Market Realist•24 days agoAnalysts Have Drastically Reduced Biogen’s Target Price in March
What Analysts Are Recommending for These Biotech Giants in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 13.56% for Biogen (BIIB) based on its closing price on March
- Motley Fool•24 days ago
Why Biogen's Alzheimer's Drug Failure May Have a Silver Lining
The Swiss pharmaceutical company halted its trial of aducanumab because it wasn't helping patients. But it could still help researchers.
- Zacks•25 days ago
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.
